700426PuMPED - Proving the Market of Point-ofcarE DiagnosticsClosedGRD Proof of MarketInnovate UKProtein biomarkers offer accurate diagnosis of a wide range of conditions but are currently only available through centralised laboratories. This makes them expensive to the healthcare system and slow to provide results, delaying the start of treatment and causing unneeded hardship for patients. Orphidia’s technology replicates the process of the laboratory in one device, bringing laboratory-accuracy measurement of biomarkers to the point of care. This will improve the speed of diagnosis and provide earlier treatment to patients, increasing their rate of recovery. We expect that Orphidia will also provide significant savings to the healthcare system itself. In this project we will improve our understanding of the market for Orphidia and the specification of a successful product. This will take the form of three activities: first we will prioritise market sectors for entry, based on the companies that are currently active in it and on emerging technologies from academia. Having identified our primary market we will invite doctors and biomarker companies to focus groups, in which we will explore how Orphidia can best accommodate their needs. Finally we will build a health economic model to calculate the benefit that our customers will derive from Orphidia. The outcomes of this project will be essential to inform further development of Orphidia’s technology. They will help us to identify the markets that we should approach first and to finalise the business case of Orphidia to biomarker companies and clinicians. Based on this project we will set target specifications for our first product, to show clearly how it addresses the needs of our customers. Successful delivery of this project will help us to unlock investment of £200k to support prototype development and a follow-up of £2m for production of the first Orphidia product.